Organon & Co. (OGN) Posts FY Adjusted EPS of $3.66, EBITDA Margin at 30.7%

Organon & Co. (NYSE:OGN) is among the 7 Oversold Pharma Stocks to Buy Now.

Organon & Co. (NYSE:OGN) is among the most oversold pharma stocks.

TheFly reported on February 12 that OGN announced its fourth-quarter and full-year 2025 financial results. According to the report, for the full year, the company’s revenue totaled $6.2 billion, which represents a 3% decline both on a reported basis and in constant currency. Diluted earnings per share were $0.72, while non-GAAP adjusted diluted EPS came in at $3.66. The company generated $1.91 billion in adjusted EBITDA, which includes $6 million in IPR&D expenses, resulting in a 30.7% adjusted EBITDA margin.

Moreover, the company also reported that looking ahead to 2026, it expects revenue of approximately $6.2 billion and adjusted EBITDA of about $1.9 billion, roughly consistent with 2025 performance.

Separately, earlier on January 28, Organon & Co. (NYSE:OGN) announced that it had finalized the sale of its JADA System to Laborie Medical Technologies Corp. The company confirmed the transaction’s completion and referred to its earlier disclosure for detailed financial terms. The JADA System is designed to manage and treat abnormal postpartum uterine bleeding or hemorrhage when conservative intervention is appropriate.

Organon & Co. (NYSE:OGN) is a global pharmaceutical company focused on women’s health, biosimilars, and established medicines, developing and commercializing treatments across reproductive health, cardiovascular, and other therapeutic areas.

While we acknowledge the potential of OGN as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the

Disclosure: None.